Skip to content
X-twitter Linkedin Youtube
  • FR
  • EN
  • FR
  • EN
  • HERV Approach
    • A novel approach
    • HERV in MS
    • HERV in Post-COVID
    • HERV in ALS
    • Other HERV-mediated diseases
    • Pipeline Overview
    • Intellectual Property
  • Post-COVID
    • HERV in Post-COVID
    • Clinical trial
    • Publications
  • Clinical Trials
  • News & Media
    • News & Press
    • Scientific publications
  • Investors
    • GNRO Shares
    • GeNeuro’s main shareholders
    • Analyst coverage
    • Stock price
    • Press releases
    • Annual reports / Registration documents
    • AMF Regulated information
    • Company governance
    • Financial events
    • Investor relations
  • About GeNeuro
    • Company Overview
    • Company History
    • The Board of GeNeuro
    • Management
    • General meetings
  • Contact
Menu
  • HERV Approach
    • A novel approach
    • HERV in MS
    • HERV in Post-COVID
    • HERV in ALS
    • Other HERV-mediated diseases
    • Pipeline Overview
    • Intellectual Property
  • Post-COVID
    • HERV in Post-COVID
    • Clinical trial
    • Publications
  • Clinical Trials
  • News & Media
    • News & Press
    • Scientific publications
  • Investors
    • GNRO Shares
    • GeNeuro’s main shareholders
    • Analyst coverage
    • Stock price
    • Press releases
    • Annual reports / Registration documents
    • AMF Regulated information
    • Company governance
    • Financial events
    • Investor relations
  • About GeNeuro
    • Company Overview
    • Company History
    • The Board of GeNeuro
    • Management
    • General meetings
  • Contact

Day: April 9, 2021

GeNeuro : financial information for the first quarter 2021

Geneva, Switzerland, April 9, 2021 – 6.00pm CEST  Strong financial situation and visibility: https://geneuro.ch/data/news/GeNeuro-PR-Q1-2021-EN.pdf

© 2025 GeNeuro SA

  • Legal Notice

 3, Chemin du Pré-Fleuri
CH-1228 Plan-les-Ouates
Geneva, Switzerland

  • +41 22 552 48 00
  • contact@geneuro.com
X-twitter Linkedin Youtube